Treatment of Fecal Incontinence and Functional Evacuation Disorders Using Non-instrumental Biofeedback

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHospital Universitari Vall d'Hebron Research Institute

About this trial

Background. Rehabilitation and re-education using instrumental anorectal biofeedback are the main treatment of anorectal functional disorders producing incontinence and outlet obstructed defecation. These treatments imply intubation of patient and several sessions of treatment leading to high consumption of resources and costs.

Hypothesis. A cognitive intervention based on original audiovisual programs developed specifically for the management of anorectal functional disorders is effective in correcting anorectal function disorders that cause fecal incontinence and evacuation disorders.

Aim. To prove in two different protocols (fecal incontinence and dyssinergic defecation) the efficacy of specifically developed non-instrumental biofeedback techniques.

Selection criteria. Patients with fecal incontinence and altered sphincter function and patients with outlet obstructed evacuation referred for biofeedback treatment.

Intervention. In separate studies (incontinence and dyssynergic defecation) patients will be randomized into biofeedback and placebo groups. One session of either biofeedback or placebo intervention will be performed at the beginning of the intervention period and patients will be instructed to performed the assigned daily treatment at home. A visit for outcome assessment will be performed at 3 months in incontinence study and at 4 weeks in the dyssinergic defecation study. In addition, in the incontinence study a phone call will be performed after 6 months of the beginning of the study to evaluate treatment outcome.

Biofeedback: patients will be taught to control anal and abdominal muscular activity by providing instructions using original video supports. Patients will be instructed to perform the same exercises daily at home in scheduled times.

Placebo: a pill of placebo containing 0.3 g glucose will be administered every day at home.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients who have at least 4 episodes of fecal incontinence during the last 14 days.

Patients able to follow instructions and attend study visits.

Patients with constipation who present less than 3 complete spontaneous bowel movements per week and/or who have Bristol 1 or Bristol 2 type stools in more than 25% of the bowel movements in the 2 weeks prior to the study

Patients able to follow instructions and attend study visits.

Disqualifiers

Patients with organic digestive diseases such as inflammatory bowel disease, celiac disease, gastro-duodenal ulcer...

Patients with neurological diseases (spinal cord injury, multiple sclerosis, Parkinson's disease).

Patients with previous of active colon and/or rectal cancer.

Patients with rectal fistula.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Biofeedback

    Behavioral

    Three visits will be made throughout the study. The first visit (Day -14) will consist of an evaluation of the inclusion criteria. A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient. The second visit will take place 14 days later (Day 0). During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria. Patients who meet the criteria will be randomized 2:1 to active treatment or placebo. Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home. A final visit will be performed at the end of the study (3 months in incontinence studies and 4 weeks in dyssynergic defecation studies). In incontinence study a final phone call will be performed at 6 months.

  • Placebo

    Behavioral

    Three visits will be made throughout the study following the same procedure as patients in the active arm. Patients randomized to placebo treatment will receive instructions to take a pill of placebo containing 0.3 g glucose daily at home. A final visit will be performed at the end of the study alike the active treatment group.

Treatment groups

96 Participants
are divided into 2 treatment groups
Group A: BiofeedbackExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Fecal incontinence study: Number of anal leaks

Number of involuntary leaks during the last 15 days of study compared to the 15 days prior to treatment start.

Time frame
3 months
2

Dyssinergic defecation study: Number of bowel movements

Number and type (according to Bristol scale) of bowel movements during the last 15 days of study compared to the 15 days prior to treatment start.

Time frame
4 weeks

Secondary outcomes

1

Incontinence study: Wexner scale

Score rated at the end of the study compared to the score rated prior to treatment start using the Wexner scale for incontinence.

Time frame
3 and 6 months
2

Incontinence study: Quality of life

Score rated at the end of the study compared to the score rated prior to treatment start using the quality of life questionnaire for incontinence (FIQoL)

Time frame
3 months
3

Incontinence study: anxiety and depression

Score rated at the end of the study compared to the score rated prior to treatment start using the hospital anxiety-depression questionnaire (HDA)

Time frame
3 months
4

Incontinence study: Anal sphincter function

Resting pressure and squeeze pressure of the anal sphincters at the end of the study compared to pressures prior to treatment start measured by anorectal manometry

Time frame
3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.